https://www3.nhk.or.jp/nhkworld/en/news/20200407_13/
Inovio Pharmaceuticals said preclinical animal studies had shown promising immune responses.
It said clinical trials of the vaccine candidate in up to 40 healthy adult volunteers began on Monday in two locations: Philadelphia, Pennsylvania and Kansas City, Missouri.
Each participant will receive two doses of the drug four weeks apart, with the goal of obtaining data on initial immune responses and safety.
The company said if everything goes well, it hopes to have 1 million doses of the vaccine available by year-end for additional trials and emergency use.
Inovio Pharmaceuticals said preclinical animal studies had shown promising immune responses.
It said clinical trials of the vaccine candidate in up to 40 healthy adult volunteers began on Monday in two locations: Philadelphia, Pennsylvania and Kansas City, Missouri.
Each participant will receive two doses of the drug four weeks apart, with the goal of obtaining data on initial immune responses and safety.
The company said if everything goes well, it hopes to have 1 million doses of the vaccine available by year-end for additional trials and emergency use.
